Adaptive immune system responding to Neisseria meningitidis serogroup A, B, C, W, and Y antigens

The adaptive immune system's response to Neisseria meningitidis antigens involves the recognition of specific bacterial components to generate protective immunity. For serogroups A, C, W, and Y, the primary antigens are capsular polysaccharides, which are typically conjugated to carrier proteins to enhance T-cell dependent responses and long-term memory (CDC, 2023). Serogroup B antigens differ because its polysaccharide mimics human tissues; therefore, vaccines use recombinant proteins such as factor H binding protein (fHbp) and Neisserial adhesin A (NadA) (StatPearls, 2023). Upon administration, these vaccines stimulate B-lymphocytes to produce serum bactericidal antibodies (SBA), which are the primary correlates of protection against invasive meningococcal disease (WHO, 2023). This immune activation prevents the bacteria from colonizing the nasopharynx and progressing to life-threatening conditions like meningitis or meningococcemia. Pentavalent vaccines (MenABCWY) have recently been developed to provide comprehensive coverage against all five major pathogenic serogroups in a single series (FDA, 2023). The resulting adaptive response includes both immediate antibody production and the establishment of immunological memory for rapid secondary responses upon future exposure. This target represents a complex interplay of antigen-presenting cells, T-helper cells, and B-cells working in concert to neutralize the pathogen.

Other names

Meningococcal vaccine antigensMenABCWY immune responseNeisseria meningitidis adaptive immunity

Induction of active humoral and cellular immune responses, specifically the production of complement-mediated bactericidal antibodies against Neisseria meningitidis.